Search

Your search keyword '"Ryu, Jay H."' showing total 2,014 results
Start Over Author "Ryu, Jay H."
2,014 results on '"Ryu, Jay H."'

2. Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms

Author

Banks, Samantha A., Decker, Paul, Flanagan, Eoin P., Zekeridou, Anastasia, Go, Ronald S., Abeykoon, Jithma P., Goyal, Gaurav, Young, Jason R., Koster, Matthew J., Vassallo, Robert, Ryu, Jay H., Davidge-Pitts, Caroline J., Ravindran, Aishwarya, Sartori Valinotti, Julio C., Bennani, N. Nora, Shah, Mithun V., Rech, Karen L., Bach, Corrie R., Eckel-Passow, Jeanette E., and Tobin, W. Oliver

Published
2024
Full Text
View/download PDF

3. Clinical features and outcomes in primary nervous system histiocytic neoplasms

Author

Nathoo, Nabeela, Uhm, Joon H., Porter, Alyx B., Hammack, Julie, Jaeckle, Kurt A., Mrugala, Maciej M., Crum, Brian A., Flanagan, Eoin P., Pittock, Sean J., Goyal, Gaurav, Young, Jason R., Koster, Matthew J., Vassallo, Robert, Ryu, Jay H., Davidge-Pitts, Caroline J., Bach, Corrie, Ravindran, Aishwarya, Sartori Valinotti, Julio C., Bennani, N. Nora, Abeykoon, Jithma P., Shah, Mithun V., Hook, C. Christopher, Rech, Karen L., Go, Ronald S., and Tobin, W. Oliver

Published
2024
Full Text
View/download PDF

10. Neurological Manifestations of Histiocytic Disorders

Author

Banks, Samantha A, Sartori Valinotti, Julio C, Go, Ronald S, Abeykoon, Jithma P, Goyal, Gaurav, Young, Jason R, Koster, Matthew J, Vassallo, Robert, Ryu, Jay H, Davidge-Pitts, Caroline J, Ravindran, Aishwarya, Bennani, N Nora, Shah, Mithun V, Rech, Karen L, and Tobin, W Oliver

Published
2023
Full Text
View/download PDF

12. Orphan Tracheopathies

Author

Maldonado, Fabien, Tomassetti, Sara, Ryu, Jay H., Cottin, Vincent, editor, Richeldi, Luca, editor, Brown, Kevin, editor, and McCormack, Francis X., editor

Published
2023
Full Text
View/download PDF

13. Long-term outcomes among adults with Langerhans cell histiocytosis

Author

Goyal, Gaurav, Acosta-Medina, Aldo A., Abeykoon, Jithma P., Dai, Chen, Ravindran, Aishwarya, Vassallo, Robert, Ryu, Jay H., Shah, Mithun V., Bennani, N. Nora, Young, Jason R., Bach, Corrie R., Ruan, Gordon J., Zanwar, Saurabh, Tobin, W. Oliver, Koster, Matthew J., Davidge-Pitts, Caroline J., Gruber, Lucinda M., Dasari, Surendra, Rech, Karen L., and Go, Ronald S.

Published
2023
Full Text
View/download PDF

15. Pulmonary manifestations in VEXAS syndrome

Author

Casal Moura, Marta, Baqir, Misbah, Tandon, Yasmeen K., Samec, Matthew J., Hines, Alexander S., Reichard, Kaaren K., Mangaonkar, Abhishek A., Go, Ronald S., Warrington, Kenneth J., Patnaik, Mrinal M., Koster, Mathew J., and Ryu, Jay H.

Published
2023
Full Text
View/download PDF

16. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis

Author

Barnes, Hayley, Morisset, Julie, Molyneaux, Philip, Westall, Glen, Glaspole, Ian, Collard, Harold R, Collaborators, CHP Exposure Assessment, Antoniou, Katerina M, Barber, Christopher M, Behr, Jürgen, Bonella, Francesco, Corte, Tamera, Costabel, Ulrich, Cottin, Vincent, Crestani, Bruno, Dalphin, Jean-Charles, Flaherty, Kevin R, Goh, Nicole, Johannson, Kerri A, Kondoh, Yasuhiro, Lederer, David, Lee, Joyce, Maher, Toby M, Martinez, Fernando J, Morell, Ferran, Noth, Imre, Raghu, Ganesh, Renzoni, Elisabetta, Richeldi, Luca, Ryerson, Christopher J, Ryu, Jay H, Salisbury, Margaret L, Singh, Sheetu, Selman, Moises, Strek, Mary E, Tarlo, Susan M, Tomassetti, Sara, Vancheri, Carlo, Vasakova, Martina, Wolters, Paul, and Wells, Athol

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Management of diseases and conditions, 7.3 Management and decision making, Alveolitis, Extrinsic Allergic, Chronic Disease, Consensus, Humans, Lung, Tomography, X-Ray Computed, extrinsic allergic alveolitis, hypersensitivity pneumonitis, interstitial lung diseases, CHP Exposure Assessment Collaborators, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

BackgroundChronic hypersensitivity pneumonitis (CHP) is an immune-mediated interstitial lung disease (ILD) caused by inhalational exposure to environmental antigens, resulting in parenchymal fibrosis. By definition, a diagnosis of CHP assumes a history of antigen exposure, but only half of all patients eventually diagnosed with CHP will have a causative antigen identified. Individual clinician variation in eliciting a history of antigen exposure may affect the frequency and confidence of CHP diagnosis.MethodsA list of potential causative exposures were derived from a systematic review of the literature. A Delphi method was applied to an international panel of ILD experts to obtain consensus regarding technique for the elicitation of exposure to antigens relevant to a diagnosis of CHP. The consensus threshold was set at 80% agreement, and median ≤ 2, interquartile range = 0 on a 5-point Likert scale (1, strongly agree; 2, tend to agree; 3, neither agree nor disagree; 4, disagree; 5, strongly disagree).ResultsIn two rounds, 36/40 experts participated. Experts agreed on 18 exposure items to ask every patient with suspected CHP. Themes included CHP inducing exposures, features that contribute to an exposure's relevance, and quantification of a relevant exposure. Based on the results from the literature review and Delphi process, a CHP exposure assessment instrument was derived. Using cognitive interviews, the instrument was revised by patients with ILD for readability and usability.ConclusionsThis Delphi survey provides items that ILD experts agree are important to ask in all patients presenting with suspected CHP and provides basis for a systematically derived CHP exposure assessment instrument. Clinical utility of this exposure assessment instrument may be affected by different local prevalence patterns of exposures. Ongoing research is required to clinically validate these items and consider their impact in more geographically diverse settings.

Published
2020

17. Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory

Author

Matson, Scott M., Baqir, Misbah, Moua, Teng, Marll, Michael, Kent, Jessica, Iannazzo, Nicholas S., Boente, Ryan D., Donatelli, John M., Dai, Junqiang, Diaz, Francisco J., Demoruelle, M. Kristen, Hamblin, Mark B., Mathai, Susan K., Ryu, Jay H., Pope, Kristen, Walker, Christopher M., and Lee, Joyce S.

Published
2023
Full Text
View/download PDF

20. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

Author

Juge, Pierre-Antoine, Lee, Joyce S, Ebstein, Esther, Furukawa, Hiroshi, Dobrinskikh, Evgenia, Gazal, Steven, Kannengiesser, Caroline, Ottaviani, Sébastien, Oka, Shomi, Tohma, Shigeto, Tsuchiya, Naoyuki, Rojas-Serrano, Jorge, González-Pérez, Montserrat I, Mejía, Mayra, Buendía-Roldán, Ivette, Falfán-Valencia, Ramcés, Ambrocio-Ortiz, Enrique, Manali, Effrosyni, Papiris, Spyros A, Karageorgas, Theofanis, Boumpas, Dimitrios, Antoniou, Katarina, van Moorsel, Coline HM, van der Vis, Joanne, de Man, Yaël A, Grutters, Jan C, Wang, Yaping, Borie, Raphaël, Wemeau-Stervinou, Lidwine, Wallaert, Benoît, Flipo, René-Marc, Nunes, Hilario, Valeyre, Dominique, Saidenberg-Kermanac’h, Nathalie, Boissier, Marie-Christophe, Marchand-Adam, Sylvain, Frazier, Aline, Richette, Pascal, Allanore, Yannick, Sibilia, Jean, Dromer, Claire, Richez, Christophe, Schaeverbeke, Thierry, Lioté, Huguette, Thabut, Gabriel, Nathan, Nadia, Amselem, Serge, Soubrier, Martin, Cottin, Vincent, Clément, Annick, Deane, Kevin, Walts, Avram D, Fingerlin, Tasha, Fischer, Aryeh, Ryu, Jay H, Matteson, Eric L, Niewold, Timothy B, Assayag, Deborah, Gross, Andrew, Wolters, Paul, Schwarz, Marvin I, Holers, Michael, Solomon, Joshua J, Doyle, Tracy, Rosas, Ivan O, Blauwendraat, Cornelis, Nalls, Mike A, Debray, Marie-Pierre, Boileau, Catherine, Crestani, Bruno, Schwartz, David A, and Dieudé, Philippe

Subjects
Epidemiology, Biomedical and Clinical Sciences, Health Sciences, Lung, Rare Diseases, Autoimmune Disease, Genetics, Clinical Research, Arthritis, Rheumatoid Arthritis, 2.1 Biological and endogenous factors, Aetiology, Inflammatory and immune system, Respiratory, Aged, Arthritis, Rheumatoid, Female, Gain of Function Mutation, Genetic Predisposition to Disease, Genotype, Humans, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial, Male, Middle Aged, Mucin-5B, Odds Ratio, Promoter Regions, Genetic, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundGiven the phenotypic similarities between rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) (hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we hypothesized that the strongest risk factor for the development of idiopathic pulmonary fibrosis, the gain-of-function MUC5B promoter variant rs35705950, would also contribute to the risk of ILD among patients with RA.MethodsUsing a discovery population and multiple validation populations, we tested the association of the MUC5B promoter variant rs35705950 in 620 patients with RA-ILD, 614 patients with RA without ILD, and 5448 unaffected controls.ResultsAnalysis of the discovery population revealed an association of the minor allele of the MUC5B promoter variant with RA-ILD when patients with RA-ILD were compared with unaffected controls (adjusted odds ratio, 3.8; 95% confidence interval [CI], 2.8 to 5.2; P=9.7×10-17). The MUC5B promoter variant was also significantly overrepresented among patients with RA-ILD, as compared with unaffected controls, in an analysis of the multiethnic case series (adjusted odds ratio, 5.5; 95% CI, 4.2 to 7.3; P=4.7×10-35) and in a combined analysis of the discovery population and the multiethnic case series (adjusted odds ratio, 4.7; 95% CI, 3.9 to 5.8; P=1.3×10-49). In addition, the MUC5B promoter variant was associated with an increased risk of ILD among patients with RA (adjusted odds ratio in combined analysis, 3.1; 95% CI, 1.8 to 5.4; P=7.4×10-5), particularly among those with evidence of usual interstitial pneumonia on high-resolution computed tomography (adjusted odds ratio in combined analysis, 6.1; 95% CI, 2.9 to 13.1; P=2.5×10-6). However, no significant association with the MUC5B promoter variant was observed for the diagnosis of RA alone.ConclusionsWe found that the MUC5B promoter variant was associated with RA-ILD and more specifically associated with evidence of usual interstitial pneumonia on imaging. (Funded by Société Française de Rhumatologie and others.).

Published
2018

26. What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?

Author

Moua, Teng, Baqir, Misbah, and Ryu, Jay H.

Subjects
IDIOPATHIC pulmonary fibrosis, PULMONARY fibrosis, COLLAGEN diseases, CELLULAR aging, OLDER people
Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal lung disease most commonly encountered in older individuals. Several decades of research have contributed to a better understanding of its pathogenesis, though only two drugs thus far have shown treatment efficacy, i.e., by slowing the decline of lung function. The pathogenesis of IPF remains incompletely understood and involves multiple complex interactions and mechanisms working in tandem or separately to result in unchecked deposition of extracellular matrix components and collagen characteristic of the disease. These mechanisms include aberrant response to injury in the alveolar epithelium, inappropriate communication between epithelial cells and mesenchymal cells, imbalances between oxidative injury and tissue repair, recruitment of inflammatory pathways that induce fibrosis, and cell senescence leading to sustained activation and proliferation of fibroblasts and myofibroblasts. Targeted approaches to each of these mechanistic pathways have led to recent clinical studies evaluating the safety and efficacy of several agents. This review highlights selected concepts in the pathogenesis of IPF as a rationale for understanding current or future therapeutic approaches, followed by a review of several selected agents and their recent or active clinical studies. Current novel therapies include approaches to attenuating or modifying specific cellular or signaling processes in the fibrotic pathway, modifying inflammatory and metabolic derangements, and minimizing inappropriate cell senescence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Rare Causes of Cystic Lung Disease

Author

Shifren, Adrian, Ryu, Jay H., Rounds, Sharon I.S., Series Editor, Dixon, Anne, Series Editor, Schnapp, Lynn M., Series Editor, Gupta, Nishant, editor, Wikenheiser-Brokamp, Kathryn A., editor, and McCormack, Francis X., editor

Published
2021
Full Text
View/download PDF

28. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey

Author

Morisset, Julie, Johannson, Kerri A, Jones, Kirk D, Wolters, Paul J, Collard, Harold R, Walsh, Simon LF, Ley, Brett, Antoniou, Katerina M, Assayag, Deborah, Behr, Juergen, Bonella, Francesco, Brown, Kevin K, Collins, Bridget F, Cormier, Yvon, Corte, Tamera J, Costabel, Ulrich, Danoff, Sonye K, de Boer, Kaïssa, Fernandez Perez, Evans R, Flaherty, Kevin R, Goh, Nicole SL, Glaspole, Ian, Jones, Mark G, Kondoh, Yasuhiro, Kreuter, Michael, Lacasse, Yves, Lancaster, Lisa H, Lederer, David J, Lee, Joyce S, Maher, Toby M, Martinez, Fernando J, Meyer, Keith C, Mooney, Joshua J, Gall, Xavier Muñoz, Noble, Paul W, Noth, Imre, Oldham, Justin M, Alberto de Castro Pereira, Carlos, Poletti, Venerino, Selman, Moises, Spagnolo, Paolo, Renzoni, Elisabetta, Richeldi, Luca, Ryerson, Christopher J, Ryu, Jay H, Salisbury, Margaret L, Strek, Mary E, Tomassetti, Sara, Valeyre, Dominique, Vancheri, Carlo, Wijsenbeek, Marlies S, and Wuyts, Wim

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Alveolitis, Extrinsic Allergic, Chronic Disease, Consensus, Delphi Technique, Female, Humans, Internationality, Male, Surveys and Questionnaires, hypersensitivity pneumonitis, interstitial lung disease, diagnosis, Delphi, HP Delphi Collaborators, Diagnosis, Hypersensitivity pneumonitis, Interstitial Lung Disease, Medical and Health Sciences, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

RationaleCurrent diagnosis of chronic hypersensitivity pneumonitis (cHP) involves considering a combination of clinical, radiological, and pathological information in multidisciplinary team discussions. However, this approach is highly variable with poor agreement between centers.ObjectivesWe aimed to identify diagnostic criteria for cHP that reach consensus among international experts.MethodsA 3-round modified Delphi survey was conducted between April and August 2017. Forty-five experts in interstitial lung disease from 14 countries participated in the online survey. Diagnostic items included in round 1 were generated using expert interviews and literature review. During rounds 1 and 2, experts rated the importance of each diagnostic item on a 5-point Likert scale. The a priori threshold of consensus was ≥ 75% of experts rating a diagnostic item as very important or important. In the third round, experts graded the items that met consensus as important and provided their level of diagnostic confidence for a series of clinical scenarios.Measurements and main resultsConsensus was achieved on 18 of the 40 diagnostic items. Among these, experts gave the highest level of importance to the identification of a causative antigen, time relation between exposure and disease, mosaic attenuation on chest imaging, and poorly formed non-necrotizing granulomas on pathology. In clinical scenarios, the diagnostic confidence of experts in cHP was heightened by the presence of these diagnostic items.ConclusionThis consensus-based approach for the diagnosis of cHP represents a first step towards the development of international guidelines for the diagnosis of cHP.

Published
2018

34. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease The SADL Model

Author

Morisset, Julie, Vittinghoff, Eric, Elicker, Brett M, Hu, Xiaowen, Le, Stephanie, Ryu, Jay H, Jones, Kirk D, Haemel, Anna, Golden, Jeffrey A, Boin, Francesco, Ley, Brett, Wolters, Paul J, King, Talmadge E, Collard, Harold R, and Lee, Joyce S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Patient Safety, Lung, Autoimmune Disease, Scleroderma, 4.2 Evaluation of markers and technologies, 4.1 Discovery and preclinical testing of markers and technologies, Respiratory, Good Health and Well Being, Cause of Death, Disease Progression, Female, Follow-Up Studies, Humans, Lung Diseases, Interstitial, Male, Middle Aged, Prognosis, Proportional Hazards Models, Prospective Studies, Risk Assessment, Risk Factors, Scleroderma, Systemic, Survival Rate, Time Factors, Tomography, X-Ray Computed, United States, interstitial lung disease, prognosis, risk prediction, systemic sclerosis, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

BackgroundInterstitial lung disease (ILD) is an important cause of morbidity and mortality in patients with scleroderma (Scl). Risk prediction and prognostication in patients with Scl-ILD are challenging because of heterogeneity in the disease course.MethodsWe aimed to develop a clinical mortality risk prediction model for Scl-ILD. Patients with Scl-ILD were identified from two ongoing longitudinal cohorts: 135 patients at the University of California, San Francisco (derivation cohort) and 90 patients at the Mayo Clinic (validation cohort). Using these two separate cohorts, a mortality risk prediction model was developed and validated by testing every potential candidate Cox model, each including three or four variables of a possible 19 clinical predictors, for time to death. Model discrimination was assessed using the C-index.ResultsThree variables were included in the final risk prediction model (SADL): ever smoking history, age, and diffusing capacity of the lung for carbon monoxide (% predicted). This continuous model had similar performance in the derivation (C-index, 0.88) and validation (C-index, 0.84) cohorts. We created a point scoring system using the combined cohort (C-index, 0.82) and used it to identify a classification with low, moderate, and high mortality risk at 3 years.ConclusionsThe SADL model uses simple, readily accessible clinical variables to predict all-cause mortality in Scl-ILD.

Published
2017

35. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease

Author

Morisset, Julie, Vittinghoff, Eric, Lee, Bo Young, Tonelli, Roberto, Hu, Xiaowen, Elicker, Brett M, Ryu, Jay H, Jones, Kirk D, Cerri, Stefania, Manfredi, Andreina, Sebastiani, Marco, Gross, Andrew J, Ley, Brett, Wolters, Paul J, King, Talmadge E, Kim, Dong Soon, Collard, Harold R, and Lee, Joyce S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Arthritis, Rare Diseases, Autoimmune Disease, Clinical Research, Prevention, Lung, Inflammatory and immune system, Respiratory, Good Health and Well Being, Aged, Arthritis, Rheumatoid, Carbon Monoxide, Female, Health Status Indicators, Humans, Idiopathic Pulmonary Fibrosis, Incidence, Longitudinal Studies, Lung Diseases, Interstitial, Male, Middle Aged, Predictive Value of Tests, Prognosis, Retrospective Studies, Tomography, X-Ray Computed, Vital Capacity, Rheumatoid arthritis, Interstitial lung disease, Risk assessment, Cardiorespiratory Medicine and Haematology, Respiratory System, Cardiovascular medicine and haematology
Abstract

BackgroundRheumatoid arthritis-associated interstitial lung disease (RA-ILD) is associated with significant morbidity and mortality. Similarities have been observed between patients with idiopathic pulmonary fibrosis (IPF) and the UIP (usual interstitial pneumonia) form of RA-ILD. The GAP (gender, age, physiology) model has been shown to predict mortality in patients with IPF, but its ability to predict mortality in RA-ILD is not known.MethodsWe identified 309 patients with RA-ILD at 4 academic centers with ongoing longitudinal cohorts of patients with ILD. The primary endpoint was mortality. To handle missing data (n = 219 subjects with complete dataset), multiple imputation by iterative chained equations was used. Using the GAP model as a baseline, we assessed improvements in mortality risk prediction achieved by incorporating additional variables. Model discrimination was assessed using the c-index, and calibration was checked by comparing observed and expected incidence of death.ResultsPatients had a mean age of 65 years and were predominantly female (54%). The mean forced vital capacity (FVC) % predicted was 73 and the mean diffusing capacity for carbon monoxide (DLCO) % predicted was 55. Twenty-four percent of the 236 patients with a high-resolution computed tomography scan available for review had a definite UIP pattern. The original GAP model, including gender, age, FVC%, and DLCO%, had a c-index of 0.746 in our cohort. Calibration of this model was satisfactory at 1, 2 and 3 years. Model discrimination was not meaningfully improved by adding other clinical variables.ConclusionThe GAP model that was derived for IPF performs similarly as a mortality risk prediction tool in RA-ILD.

Published
2017

36. A 62-Year-Old Woman With Cough, Dyspnea, and Diffuse Lung Nodules.

Author

Wireko, Felix W., DeMartino, Erin S., Walkoff, Lara A., Boland, Jennifer M., and Ryu, Jay H.

Subjects
PULMONARY nodules, COUGH, TYPE 1 diabetes, DYSPNEA, LUNG diseases
Abstract

A 62-year-old woman came to our hospital with worsening cough and dyspnea over the preceding week, during which time she had been treated with azithromycin and prednisone for suspected pneumonia. She had no fever, chills, or sweats, but her cough had become productive of clear to blood-tinged phlegm during the interval. Medical history was significant for insulin-dependent diabetes mellitus and OSA. She had quit smoking 44 years earlier and had no history of lung disease. She was a bank teller residing in southeastern Minnesota and described no relevant inhalational or environmental exposures, drug use, aspiration, or travels preceding her illness. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study

Author

Tomassetti, Sara, Ravaglia, Claudia, Wells, Athol U, Cavazza, Alberto, Colby, Thomas V, Rossi, Giulio, Ley, Brett, Ryu, Jay H, Puglisi, Silvia, Arcadu, Antonella, Marchi, Martina, Sultani, Fabio, Martinello, Sabrina, Donati, Luca, Gurioli, Carlo, Gurioli, Christian, Tantalocco, Paola, Hetzel, Jurgen, Dubini, Alessandra, Piciucchi, Sara, Klersy, Catherine, Lavorini, Federico, and Poletti, Venerino

Published
2020
Full Text
View/download PDF

42. Chronic Cough Due to Stable Chronic Bronchitis: CHEST Expert Panel Report

Author

Adams, Todd M., Altman, Kenneth W., Azoulay, Elie, Barker, Alan F., Birring, Surinder S., Blackhall, Fiona, Bolser, Donald C., Boulet, Louis-Philippe, Braman, Sidney S., Brightling, Christopher, Callahan-Lyon, Priscilla, Chang, Anne B., Davenport, Paul, El Solh, Ali A., Escalante, Patricio, Field, Stephen K., Fisher, Dina, French, Cynthia T., Gibson, Peter, Grant, Cameron, Harding, Susan M., Harnden, Anthony, Hill, Adam T., Irwin, Richard S., Kahrilas, Peter J., Kavanagh, Joanne, Keogh, Karina A., Lai, Kefang, Lane, Andrew P., Lilly, Craig, Lim, Kaiser, Lown, Mark, Madison, J. Mark, Malesker, Mark A., Mazzone, Stuart, McGarvey, Lorcan, Molassoitis, Alex, Murad, M. Hassan, Narasimhan, Mangala, Oppenheimer, John, Rosen, Mark, Rubin, Bruce, Russell, Richard J., Ryu, Jay H., Singh, Sonal, Smith, Maeve P., Tarlo, Susan M., Vertigan, Anne E., and Ireland, Belinda

Published
2020
Full Text
View/download PDF

43. Managing Chronic Cough as a Symptom in Children and Management Algorithms: CHEST Guideline and Expert Panel Report

Author

Adams, Todd M., Altman, Kenneth W., Azoulay, Elie, Blackhall, Fiona, Birring, Surinder S., Bolser, Donald C., Boulet, Louis-Philippe, Braman, Sidney S., Brightling, Christopher, Callahan-Lyon, Priscilla, Chang, Anne B., Cowley, Terrie, Davenport, Paul, El Solh, Ali A., Escalante, Patricio, Field, Stephen K., Fisher, Dina, French, Cynthia T., Grant, Cameron, Harding, Susan M., Harnden, Anthony, Hill, Adam T., Irwin, Richard S., Kahrilas, Peter J., Kavanagh, Joanne, Keogh, Karina A., Lai, Kefang, Lane, Andrew P., Lilly, Craig, Lim, Kaiser, Lown, Mark, Madison, J. Mark, Malesker, Mark A., Mazzone, Stuart, McGarvey, Lorcan, Molasoitis, Alex, Murad, M. Hassan, Narasimhan, Mangala, Oppenheimer, John, Russell, Richard J., Ryu, Jay H., Singh, Sonal, Smith, Maeve P., Tarlo, Susan M., Vertigan, Anne E., and Oppenheimer, John J.

Published
2020
Full Text
View/download PDF

45. Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report

Author

Altman, Kenneth W., Azoulay, Elie, Barker, Alan F., Blackhall, Fiona, Bolser, Donald C., Birring, Surinder S., Braman, Sidney S., Brightling, Christopher, Callahan-Lyon, Priscilla, Chang, Anne B., Cowley, Terrie, Davenport, Paul, El Solh, Ali A., Escalante, Patricio, Field, Stephen K., Fisher, Dina, French, Cynthia T., Grant, Cameron, Gibson, Peter, Harding, Susan M., Harnden, Anthony, Hill, Adam T., Irwin, Richard S., Kahrilas, Peter J., Kavanagh, Joanne, Lai, Kefang, Lane, Andrew P., Lilly, Craig, Lown, Mark, Madison, J. Mark, Malesker, Mark A., Mazzone, Stuart, McGarvey, Lorcan, Molasoitis, Alex, Moore, Abigail, Murad, M. Hassan, Narasimhan, Mangala, Oppenheimer, John, Rosen, Mark, Rubin, Bruce, Russell, Richard J., Ryu, Jay H., Singh, Sonal, Smith, Jaclyn, Smith, Maeve P., Tarlo, Susan M., Vertigan, Anne E., Weinberger, Miles, Côté, Andreanne, Boulet, Louis-Philippe, Gibson, Peter G., and Brightling, Christopher E.

Published
2020
Full Text
View/download PDF

46. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis

Author

Antoniou, Katerina M., Barber, Christopher M., Behr, Jürgen, Bonella, Francesco, Corte, Tamera, Costabel, Ulrich, Cottin, Vincent, Crestani, Bruno, Dalphin, Jean-Charles, Flaherty, Kevin R., Goh, Nicole, Johannson, Kerri A., Kondoh, Yasuhiro, Lederer, David, Lee, Joyce, Maher, Toby M., Martinez, Fernando J., Morell, Ferran, Noth, Imre, Raghu, Ganesh, Renzoni, Elisabetta, Richeldi, Luca, Ryerson, Christopher J., Ryu, Jay H., Salisbury, Margaret L., Singh, Sheetu, Selman, Moises, Strek, Mary E., Tarlo, Susan M., Tomassetti, Sara, Vancheri, Carlo, Vasakova, Martina, Wolters, Paul, Wells, Athol, Barnes, Hayley, Morisset, Julie, Molyneaux, Philip, Westall, Glen, Glaspole, Ian, and Collard, Harold R.

Published
2020
Full Text
View/download PDF

47. Acute Cough Due to Acute Bronchitis in Immunocompetent Adult Outpatients: CHEST Expert Panel Report

Author

Adams, Todd M., Altman, Kenneth W., Azoulay, Elie, Barker, Alan F., Blackhall, Fiona, Birring, Surinder S., Bolser, Donald C., Boulet, Louis-Philippe, Braman, Sidney S., Brightling, Christopher, Callahan-Lyon, Priscilla, Chang, Anne B., Cowley, Terrie, Davenport, Paul, El Solh, Ali A., Escalante, Patricio, Field, Stephen K., Fisher, Dina, French, Cynthia T., Grant, Cameron, Harding, Susan M., Harnden, Anthony, Hill, Adam T., Irwin, Richard S., Kahrilas, Peter J., Kavanagh, Joanne, Lai, Kefang, Lilly, Craig, Lown, Mark, Madison, J. Mark, Malesker, Mark A., Mazzone, Stuart, McGarvey, Lorcan, Molasoitis, Alex, Murad, M. Hassan, Narasimhan, Mangala, Newcombe, Peter, Oppenheimer, John, Rosen, Mark, Rubin, Bruce, Russell, Richard J., Ryu, Jay H., Singh, Sonal, Smith, Jaclyn, Smith, Maeve P., Tarlo, Susan M., Vertigan, Anne E., Weinberger, Miles, Ireland, Belinda, and Linder, Jeffrey A.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results